JPH09512536A - 修飾乳成長因子 - Google Patents
修飾乳成長因子Info
- Publication number
- JPH09512536A JPH09512536A JP7527879A JP52787995A JPH09512536A JP H09512536 A JPH09512536 A JP H09512536A JP 7527879 A JP7527879 A JP 7527879A JP 52787995 A JP52787995 A JP 52787995A JP H09512536 A JPH09512536 A JP H09512536A
- Authority
- JP
- Japan
- Prior art keywords
- modified
- growth
- milk
- growth factors
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical class C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title claims description 13
- 239000003102 growth factor Substances 0.000 claims abstract description 58
- 235000013336 milk Nutrition 0.000 claims abstract description 55
- 239000008267 milk Substances 0.000 claims abstract description 55
- 210000004080 milk Anatomy 0.000 claims abstract description 55
- 239000000284 extract Substances 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 230000012010 growth Effects 0.000 claims abstract description 39
- 230000020477 pH reduction Effects 0.000 claims abstract description 29
- 230000001737 promoting effect Effects 0.000 claims abstract description 18
- 238000004113 cell culture Methods 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 8
- 206010052428 Wound Diseases 0.000 claims abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 7
- 230000007935 neutral effect Effects 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 231100000397 ulcer Toxicity 0.000 claims abstract description 5
- 235000013365 dairy product Nutrition 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 23
- 239000012091 fetal bovine serum Substances 0.000 claims description 19
- 239000002609 medium Substances 0.000 claims description 17
- 239000005862 Whey Substances 0.000 claims description 16
- 102000007544 Whey Proteins Human genes 0.000 claims description 16
- 108010046377 Whey Proteins Proteins 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 239000002808 molecular sieve Substances 0.000 claims description 15
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 15
- 230000002378 acidificating effect Effects 0.000 claims description 14
- 238000000108 ultra-filtration Methods 0.000 claims description 14
- 210000004102 animal cell Anatomy 0.000 claims description 8
- 239000007952 growth promoter Substances 0.000 claims description 8
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003729 cation exchange resin Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 7
- 235000013351 cheese Nutrition 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000007670 refining Methods 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 238000004945 emulsification Methods 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010061172 Gastrointestinal injury Diseases 0.000 abstract 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 abstract 1
- 235000020167 acidified milk Nutrition 0.000 abstract 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 238000004587 chromatography analysis Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000003098 myoblast Anatomy 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000012466 permeate Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 235000021277 colostrum Nutrition 0.000 description 6
- 210000003022 colostrum Anatomy 0.000 description 6
- 238000005277 cation exchange chromatography Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 241000079902 Tralia Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 241000893859 Matelea Species 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 102000028718 growth factor binding proteins Human genes 0.000 description 1
- 108091009353 growth factor binding proteins Proteins 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.複数の修飾乳成長因子の製造法において、 塩基性ないしほぼ中性の等電点を有する複数の乳成長因子を含む乳製品エキス および酸源を用意し、 酸源を用いて該乳製品エキスを短時間酸性にし、 短時間酸性にした乳製品エキスから複数の修飾乳成長因子を単離する 工程を含む上記方法。 2.乳製品エキスをおよそ3.0またはそれより下のpHに短時間酸性にする 、請求項1記載の方法。 3.単離工程は、短時間酸性にした乳製品エキスを酸性条件下で精製工程にか けて不活性タンパク質を除去する処理を含む、請求項2記載の方法。 4.精製工程は、短時間酸性にした乳製品エキスをモレキュラーシーブ クロ マトグラフィー法にかける処理を含む、請求項3記載の方法。 5.精製工程は、約30kDaより大きい分子を除外する膜を使用する調節さ れた細孔限外濾過法を含む、請求項3記載の方法。 6.乳製品エキスはチーズホエーエキスである、請求項1記載の方法。 7.乳または乳製品の給源、 陽イオン交換樹脂、および 緩衝剤溶液 を用意し、 該乳または乳製品を陽イオン交換樹脂と接触させて乳または乳製品のより塩基 性の成分を樹脂上に吸収させ、 陽イオン交換樹脂を緩衝剤溶液で溶離し、そして 乳製品エキスを集める ことにより乳製品エキスを得る予備工程を含む、請求項1記載の方法。 8.乳製品エキスはGFE−2あるいは同様な成長促進剤を含む、請求項7記 載の方法。 9.高度の成長刺激活性を示しかつ約6.0以上の等電点と約5000から3 0,000の範囲の分子量を有し、乳成長因子を短時間の酸性化により修飾した 複数の修飾乳成長因子。 10.修飾GFE−2あるいは同様な成長促進剤である、請求項9記載の複数の 修飾乳成長因子。 11.請求項1から請求項8のいずれか1に記載の方法により製造された、請求 項9記載の複数の修飾乳成長因子。 12.高度の成長剌激活性を示す成長促進組成物において、約6.0以上の等電 点と約5000から30,000の範囲の分子量を有し、乳成長因子を短時間の 酸性化により修飾した複数の修飾乳成長因子を含む上記組成物。 13.複数の修飾乳成長因子は修飾GFE−2あるいは同様な成長促進剤である 、請求項12記載の成長促進組成物。 14.請求項1から請求項8のいずれか1項に記載の方法により製造された複数 の修飾乳成長因子を含む、請求項12記載のの成長促進組成物。 15.高度の成長剌激活性を発揮し、約6.0以上の等電点と約5000から3 0,000の範囲の分子量を有し、短時間の酸性化により修飾された複数の修飾 乳成長因子を含有する有効量の成長促進組成物および培地を含む細胞培養組成物 。 16.複数の修飾乳成長因子は修飾GFE−2あるいは同様な成長促進剤である 、請求項15記載の細胞培養組成物。 17.請求項1から請求項8のいずれか1項に記載の方法により製造された複数 の修飾乳成長因子を含む、請求項15記載の細胞培養組成物。 18.培地は実質的に無タンパク質培地である、請求項15記載の細胞培養組成 物。 19.培地はウシ胎児血清を含む、請求項15記載の細胞培養組成物。 20.ヒトあるいは動物の細胞を培養する方法において、動物細胞源、および 約6.0以上の等電点と約5000から30,000の範囲の分子量を有する 複数の修飾乳成長因子を含み、該乳成長因子は短時間の酸性化により修飾された ものであり、そして高度の成長剌激活性を発揮する有効量の成長促進組成物を含 む細胞培養組成物、および 培地 を用意し、そして 細胞を前記細胞培養組成物中で、予定の細胞濃度に到達するのに十分な時間、 十分な温度で培養する 工程を含む上記方法。 21.表面の傷の治療用医薬品組成物あるいは獣医学用組成物において、 約6.0以上の等電点と約5000から30,000の範囲の分子量を有し、 短時間の酸性化により修飾した複数の修飾乳成長因子、および 製薬上または獣医学上容認しうる希釈剤、担体または付形薬 を含有してなる上記組成物。 22.胃腸の損傷、諸疾患あるいは潰瘍の治療用医薬品組成物あるいは獣医学用 組成物において、 約6.0以上の等電点と約5000から30,000の範囲の分子量を有し、 短時間の酸性化により修飾した複数の修飾乳成長因子、および 製薬上あるいは獣医学上容認しうる希釈剤、担体または付形薬 を含有してなる上記組成物。 23.ヒトを含めて動物の表面の傷の治療法において、治療すべき患者へ、 約6.0以上の等電点と約5000から30,000の範囲の分子量を有し、 短時間の酸性化により修飾された複数の修飾乳成長因子、および 製薬上あるいは獣医学上容認しうる希釈剤、担体または付形薬 を含有してなる有効量の医薬品組成物あるいは獣医学用組成物を投与することか らなる上記方法。 24.胃腸の損傷、諸疾患または潰瘍の治療法において、治療すべき患者へ、 約6.0以上の等電点と約5000から30,000の範囲の分子量を有し、 短時間の酸性化により修飾された複数の修飾乳成長因子、および 製薬上あるいは獣医学上容認しうる希釈剤、担体または付形薬 を含有してなる有効量の医薬品組成物あるいは獣医学用組成物を投与することか らなる上記方法。 25.例1から例6のいずれか一つに関して実質的に説明された複数の修飾乳成 長因子。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPM5347A AUPM534794A0 (en) | 1994-04-28 | 1994-04-28 | Modified milk growth factor |
AU5347 | 1994-04-28 | ||
PCT/AU1995/000237 WO1995029933A1 (en) | 1994-04-28 | 1995-04-26 | Modified milk growth factor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09512536A true JPH09512536A (ja) | 1997-12-16 |
JP3640965B2 JP3640965B2 (ja) | 2005-04-20 |
Family
ID=3779922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52787995A Expired - Fee Related JP3640965B2 (ja) | 1994-04-28 | 1995-04-26 | 修飾乳成長因子 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6194208B1 (ja) |
EP (1) | EP0759029B1 (ja) |
JP (1) | JP3640965B2 (ja) |
AT (1) | ATE181924T1 (ja) |
AU (1) | AUPM534794A0 (ja) |
CA (1) | CA2188654C (ja) |
DE (1) | DE69510669T2 (ja) |
NZ (2) | NZ284389A (ja) |
WO (1) | WO1995029933A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016500662A (ja) * | 2012-10-08 | 2016-01-14 | マレー・ゴールバーン・コー−オペラティヴ・カンパニー・リミテッド | 乳汁から成長因子を精製するための改良されたプロセスおよびその製品 |
KR20210090560A (ko) * | 2020-01-09 | 2021-07-20 | 세종대학교산학협력단 | 세포 배양용 소태아혈청 대체 소재 |
WO2023127960A1 (ja) * | 2021-12-28 | 2023-07-06 | 日本ハム株式会社 | 筋組織由来細胞の分化の抑制剤 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN271295A0 (en) * | 1995-05-02 | 1995-05-25 | Gropep Pty Ltd | Method of treatment |
EP0894094B1 (de) * | 1996-03-15 | 2005-05-11 | BioEqual AG | Verfahren zur gewinnung eines komplexes aus wachstumsfaktoren |
US5772999A (en) * | 1996-07-30 | 1998-06-30 | Dcv Biologics, L.P. | Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals |
GB9619660D0 (en) * | 1996-09-20 | 1996-11-06 | Scient Hospital Suppl Int Ltd | Prevention of gastrointestinal damage |
NL1005677C2 (nl) * | 1997-03-27 | 1998-09-29 | Campina Melkunie Bv | Werkwijze voor het winnen van groeifactoren, of een samenstelling die één of meer groeifactoren bevat, uit melk of een derivaat daarvan. |
ES2139525B1 (es) * | 1997-11-17 | 2000-10-16 | Sanchez Pedro Cuevas | Empleo de derivados del lactosuero como citoprotectores y cicatrizantes. |
AUPQ878600A0 (en) * | 2000-07-13 | 2000-08-03 | Gropep Pty Ltd | Compositions and methods for the treatment of intact skin |
MXPA04002387A (es) * | 2001-09-12 | 2004-11-22 | Eastern Virginia Med School | Factor inhibidor de afluencia de calcio y metodo de aislamiento del mismo. |
GB0209384D0 (en) | 2002-04-24 | 2002-06-05 | Pepsyn Ltd | Peptide composition |
US20060240116A1 (en) * | 2005-04-22 | 2006-10-26 | David Jolley | Bioactive factors in wound healing topical compositions and methods |
US7572474B2 (en) | 2005-06-01 | 2009-08-11 | Mead Johnson Nutrition Company | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants |
US8075934B2 (en) * | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
US8367354B2 (en) | 2008-10-24 | 2013-02-05 | Mead Johnson Nutrition Company | Methods for determining the levels of TGF-β in a composition |
US8350006B2 (en) * | 2008-10-24 | 2013-01-08 | Mead Johnson Nutrition Company | Methods for determining the bioactivity of TGF-β in a composition |
US8986769B2 (en) | 2008-10-24 | 2015-03-24 | Mead Johnson Nutrition Company | Methods for preserving endogenous TGF-β |
WO2023079080A1 (en) | 2021-11-05 | 2023-05-11 | Frieslandcampina Nederland B.V. | Use of tgf in the prevention virus infection of the respiratory tract |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440860A (en) * | 1980-01-18 | 1984-04-03 | The Children's Medical Center Corporation | Stimulating cell growth |
IE54979B1 (en) * | 1982-07-09 | 1990-04-11 | Bridel Laiteries | Process for treating milk with a cation-exchange resin for the preparation of decationised,acidified milk |
US5077276A (en) | 1985-08-22 | 1991-12-31 | Gropep Pty Ltd | Growth factor |
US5221734A (en) * | 1987-10-01 | 1993-06-22 | Ciba-Geigy Corporation | Process for preparing a polypeptide growth factor for milk |
GB8723094D0 (en) | 1987-10-01 | 1987-11-04 | Ciba Geigy Ag | Polypeptide growth factor from milk |
DK513589A (da) | 1988-10-20 | 1990-04-21 | Smithkline Beecham Corp | Human epitelcelleomdannende vaekstfaktor og fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende vaekstfaktoren |
JPH03236772A (ja) * | 1990-02-13 | 1991-10-22 | Snow Brand Milk Prod Co Ltd | 新規な細胞増殖促進物質及びこれを有効成分とする細胞培養培地添加物 |
FR2663816B1 (fr) * | 1990-06-28 | 1993-08-06 | Clar | Procede de traitement du colostrum par chromatographie d'adsorption sur hydroxyapatite, fraction active de colostrum obtenue et milieu cellulaire contenant ladite fraction active. |
DE69133442T2 (de) * | 1990-07-13 | 2006-01-12 | Gropep Ltd., Thebarton | Wachstumsfördernder wirkstoff |
DE69128283T2 (de) | 1991-08-12 | 1998-03-19 | Nestle Sa | Nahrungsmittelzusammensetzung |
FI91166C (fi) * | 1991-10-17 | 1994-05-25 | Valio Biotuotteet Oy | Ternimaitofraktio, menetelmä sen valmistamiseksi ja sen käyttö kasvualustojen täydennysaineena |
US5281582A (en) * | 1992-02-27 | 1994-01-25 | Alliance Pharmaceuticals, Corp. | Serum growth factor |
WO1993020713A1 (en) | 1992-04-22 | 1993-10-28 | Bopa Ireland Limited | Products derived from whey and their use in foodstuffs |
NL1005677C2 (nl) | 1997-03-27 | 1998-09-29 | Campina Melkunie Bv | Werkwijze voor het winnen van groeifactoren, of een samenstelling die één of meer groeifactoren bevat, uit melk of een derivaat daarvan. |
-
1994
- 1994-04-28 AU AUPM5347A patent/AUPM534794A0/en not_active Abandoned
-
1995
- 1995-04-26 DE DE69510669T patent/DE69510669T2/de not_active Expired - Lifetime
- 1995-04-26 EP EP95916503A patent/EP0759029B1/en not_active Expired - Lifetime
- 1995-04-26 CA CA002188654A patent/CA2188654C/en not_active Expired - Fee Related
- 1995-04-26 JP JP52787995A patent/JP3640965B2/ja not_active Expired - Fee Related
- 1995-04-26 AT AT95916503T patent/ATE181924T1/de not_active IP Right Cessation
- 1995-04-26 US US08/718,409 patent/US6194208B1/en not_active Expired - Lifetime
- 1995-04-26 NZ NZ284389A patent/NZ284389A/en not_active IP Right Cessation
- 1995-04-26 WO PCT/AU1995/000237 patent/WO1995029933A1/en active IP Right Grant
-
1997
- 1997-02-21 NZ NZ314284A patent/NZ314284A/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016500662A (ja) * | 2012-10-08 | 2016-01-14 | マレー・ゴールバーン・コー−オペラティヴ・カンパニー・リミテッド | 乳汁から成長因子を精製するための改良されたプロセスおよびその製品 |
KR20210090560A (ko) * | 2020-01-09 | 2021-07-20 | 세종대학교산학협력단 | 세포 배양용 소태아혈청 대체 소재 |
WO2023127960A1 (ja) * | 2021-12-28 | 2023-07-06 | 日本ハム株式会社 | 筋組織由来細胞の分化の抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
NZ284389A (en) | 1997-04-24 |
CA2188654A1 (en) | 1995-11-09 |
DE69510669T2 (de) | 1999-10-28 |
JP3640965B2 (ja) | 2005-04-20 |
DE69510669D1 (de) | 1999-08-12 |
AUPM534794A0 (en) | 1994-05-19 |
EP0759029B1 (en) | 1999-07-07 |
CA2188654C (en) | 2007-04-24 |
NZ314284A (en) | 2000-06-23 |
WO1995029933A1 (en) | 1995-11-09 |
EP0759029A4 (en) | 1997-06-04 |
ATE181924T1 (de) | 1999-07-15 |
US6194208B1 (en) | 2001-02-27 |
EP0759029A1 (en) | 1997-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09512536A (ja) | 修飾乳成長因子 | |
JP4573182B2 (ja) | 成長促進剤 | |
JP4688092B2 (ja) | 活性型TGF−βが濃縮されたタンパク質画分を得る方法、タンパク質画分および治療的適用 | |
US5387746A (en) | Pulmonary hydrophobic surfactant-associated protein of 6,000 daltons molecular weight and multimers thereof | |
JPS6011424A (ja) | 繊維芽細胞成長因子の精製および特性表示 | |
PT88626B (pt) | Processo para a preparacao de um factor de crescimento polipeptidico proveniente de leite | |
US20090081181A1 (en) | Isolation of growth and differentiating factors from colostrum | |
JP3285862B2 (ja) | 活性依存性神経栄養因子 | |
US6319522B1 (en) | Growth-promoting agent | |
JPS63503222A (ja) | 肺の疎水性界面活性物質に結合した分子量6,000ダルトンのタンパク質及びその多量体 | |
JP2000504206A (ja) | 新規形態のアンフィレグリン、その製造方法および使用方法、ならびにそれを含む組成物 | |
JPH06508111A (ja) | 甲状腺由来の軟骨細胞刺激因子 | |
AU702002B2 (en) | Modified milk growth factor | |
US7033610B2 (en) | Growth-promoting agent | |
JPS6245530A (ja) | 肝実質細胞増殖因子 | |
US4436816A (en) | Cell growth promoting material | |
JP2802508B2 (ja) | 神経栄養ペプチド | |
JPS58192827A (ja) | 神経生長促進作用を有する新規物質 | |
JPS59175438A (ja) | ヒト妊娠特異抗原の製造方法 | |
JPH07267994A (ja) | 新規蛋白質及びその製造法 | |
JP2000503531A (ja) | 非ヒト哺乳動物由来のベータカゼインを実質的に含まない乳から誘導された生産物及び関連する使用 | |
JPS58159416A (ja) | 脳下垂体ホルモンヘパトトロピン及びその製造法 | |
JPH03246230A (ja) | 副甲状腺ホルモン及び/または副甲状腺ホルモン様たんぱくを配合した栄養組成物 | |
JPS63218700A (ja) | 新規蛋白質およびその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041015 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050120 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080128 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090128 Year of fee payment: 4 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090128 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100128 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110128 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110128 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120128 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120128 Year of fee payment: 7 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130128 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130128 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |